Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
04
08
2020
revised:
03
11
2020
accepted:
09
11
2020
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Localized pancreatic cancer is commonly treated with stereotactic body radiation therapy (SBRT), which often requires the placement of fiducial markers. We compared the clinical outcomes of patients with and without fiducial markers. We retrospectively collected data on patients with pancreatic cancer treated with neoadjuvant SBRT at a single institution. Patients were divided into 2 groups based on the placement of a fiducial marker. Local recurrence was the primary outcome. Time to event endpoints were analyzed using COX regression. We included 96 patients with unresectable pancreatic cancer: 46 patients (47.9%) did not have a fiducial marker, and 50 patients (52.1%) had a fiducial placed. Patients in the fiducial group were older and had more locally advanced pancreatic cancer compared with those who did not have a fiducial placed. Most patients in both groups (92.7%) received chemotherapy before SBRT treatment. SBRT was delivered to a median of 36 Gy over 5 fractions in the no-fiducial group, and 38 Gy over 5 fractions in the fiducial group. At a median follow-up of 20 months, local recurrence was similar irrespective of fiducial placement (adjusted hazard ratio [aHR] 0.6, 95% CI 0.3-1.3, Our data suggest that the use of fiducial markers does not negatively affect clinical outcomes in patients with localized pancreatic cancer. Prospective confirmation of our results is still needed.
Identifiants
pubmed: 33912734
doi: 10.1016/j.adro.2020.11.006
pii: S2452-1094(20)30351-1
pmc: PMC8071717
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100621Informations de copyright
© 2020 The Authors.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Pract Radiat Oncol. 2019 Sep - Oct;9(5):322-332
pubmed: 31474330
Adv Radiat Oncol. 2018 Oct 23;3(4):693-700
pubmed: 30370371
Surgery. 2018 May;163(5):1090-1096
pubmed: 29395234
Gastrointest Endosc. 2019 Apr;89(4):659-670.e18
pubmed: 30445001
Radiographics. 2016 May-Jun;36(3):675-87
pubmed: 27163588
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3
pubmed: 16168826
Ann Surg Oncol. 2015 Jul;22(7):2352-8
pubmed: 25564157
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1420-6
pubmed: 20399033
Gastrointest Endosc. 2018 Dec;88(6):926-934
pubmed: 29981302
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):181-8
pubmed: 21549517
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
World J Surg Oncol. 2019 Aug 5;17(1):134
pubmed: 31382964
Cancer. 2015 Apr 1;121(7):1128-37
pubmed: 25538019
Pract Radiat Oncol. 2020 Nov - Dec;10(6):e495-e507
pubmed: 32061993
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Arch Pathol Lab Med. 2009 Mar;133(3):413-22
pubmed: 19260747
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Curr Probl Cancer. 2020 Dec;44(6):100607
pubmed: 32471736
Eur J Cancer. 2014 Nov;50(17):2983-93
pubmed: 25256896
Radiat Oncol. 2019 Jun 6;14(1):95
pubmed: 31171025
Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1017-21
pubmed: 15001240
J Clin Oncol. 2019 Aug 10;37(23):2082-2088
pubmed: 31180816